Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Adam B. Murphy, Ramona Bhatia, Iman K. Martin, David A. Klein, Courtney M P Hollowell, Yaw Nyame, Elodi Dielubanza, Chad Achenbach, Rick A Kittles

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: HIV-infected (HIV+) men face cancer treatment disparities that impact outcome. Prostate cancer treatment and treatment appropriateness in HIV+men are unknown. Methods: We used electronic chart review to conduct a retrospective cohort study of 43 HIV+cases with prostate cancer and 86 age- and race-matched HIV-uninfected (HIV-) controls with prostate cancer, ages 40 to 79 years, from 2001 to 2012. We defined treatment appropriateness using National Comprehensive Cancer Network guidelines and the Charlson comorbidity index (CCI) to estimate life expectancy. Results: Median age was 59.5 years at prostate cancer diagnosis. Median CD4+T-cell count was 459.5 cells/ mm3, 95.3% received antiretroviral therapy, and 87.1% were virally suppressed. Radical prostatectomy was the primary treatment for 39.5% of HIV+and 71.0% of HIV- men (P = 0.004). Only 16.3% of HIV+versus 57.0% of HIV- men received open radical prostatectomy (P < 0.001). HIV+men received more radiotherapy (25.6% vs. 16.3%, P = 0.13). HIV was negatively associated with open radical prostatectomy (OR = 0.03, P = 0.007), adjusting for insurance and CCI. No men were undertreated. Fewer HIV+men received appropriate treatment (89.2% vs. 100%, P = 0.003), due to four overtreated HIV+men. Excluding AIDS from the CCI still resulted in fewer HIV+men receiving appropriate treatment (94.6% vs. 100%, P = 0.03). Conclusion: Prostate cancer in HIV+men is largely appropriately treated. Under- or overtreatment may occur from difficulties in life expectancy estimation. HIV+men may receive more radiotherapy and fewer radical prostatectomies, specifically open radical prostatectomies. Impact: Research on HIV/AIDS survival indices and etiologies and outcomes of this prostate cancer treatment disparity in HIV+men are needed.

Original languageEnglish (US)
Pages (from-to)2009-2018
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Prostatic Neoplasms
HIV
Prostatectomy
Therapeutics
Comorbidity
Life Expectancy
Acquired Immunodeficiency Syndrome
Radiotherapy
CD4 Lymphocyte Count
Insurance
Neoplasms
Cohort Studies

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Are HIV-infected men vulnerable to prostate cancer treatment disparities? / Murphy, Adam B.; Bhatia, Ramona; Martin, Iman K.; Klein, David A.; Hollowell, Courtney M P; Nyame, Yaw; Dielubanza, Elodi; Achenbach, Chad; Kittles, Rick A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 10, 01.10.2014, p. 2009-2018.

Research output: Contribution to journalArticle

Murphy, AB, Bhatia, R, Martin, IK, Klein, DA, Hollowell, CMP, Nyame, Y, Dielubanza, E, Achenbach, C & Kittles, RA 2014, 'Are HIV-infected men vulnerable to prostate cancer treatment disparities?', Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 10, pp. 2009-2018. https://doi.org/10.1158/1055-9965.EPI-14-0614
Murphy, Adam B. ; Bhatia, Ramona ; Martin, Iman K. ; Klein, David A. ; Hollowell, Courtney M P ; Nyame, Yaw ; Dielubanza, Elodi ; Achenbach, Chad ; Kittles, Rick A. / Are HIV-infected men vulnerable to prostate cancer treatment disparities?. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 10. pp. 2009-2018.
@article{f083ba450d944056b1356ef1531cf7eb,
title = "Are HIV-infected men vulnerable to prostate cancer treatment disparities?",
abstract = "Background: HIV-infected (HIV+) men face cancer treatment disparities that impact outcome. Prostate cancer treatment and treatment appropriateness in HIV+men are unknown. Methods: We used electronic chart review to conduct a retrospective cohort study of 43 HIV+cases with prostate cancer and 86 age- and race-matched HIV-uninfected (HIV-) controls with prostate cancer, ages 40 to 79 years, from 2001 to 2012. We defined treatment appropriateness using National Comprehensive Cancer Network guidelines and the Charlson comorbidity index (CCI) to estimate life expectancy. Results: Median age was 59.5 years at prostate cancer diagnosis. Median CD4+T-cell count was 459.5 cells/ mm3, 95.3{\%} received antiretroviral therapy, and 87.1{\%} were virally suppressed. Radical prostatectomy was the primary treatment for 39.5{\%} of HIV+and 71.0{\%} of HIV- men (P = 0.004). Only 16.3{\%} of HIV+versus 57.0{\%} of HIV- men received open radical prostatectomy (P < 0.001). HIV+men received more radiotherapy (25.6{\%} vs. 16.3{\%}, P = 0.13). HIV was negatively associated with open radical prostatectomy (OR = 0.03, P = 0.007), adjusting for insurance and CCI. No men were undertreated. Fewer HIV+men received appropriate treatment (89.2{\%} vs. 100{\%}, P = 0.003), due to four overtreated HIV+men. Excluding AIDS from the CCI still resulted in fewer HIV+men receiving appropriate treatment (94.6{\%} vs. 100{\%}, P = 0.03). Conclusion: Prostate cancer in HIV+men is largely appropriately treated. Under- or overtreatment may occur from difficulties in life expectancy estimation. HIV+men may receive more radiotherapy and fewer radical prostatectomies, specifically open radical prostatectomies. Impact: Research on HIV/AIDS survival indices and etiologies and outcomes of this prostate cancer treatment disparity in HIV+men are needed.",
author = "Murphy, {Adam B.} and Ramona Bhatia and Martin, {Iman K.} and Klein, {David A.} and Hollowell, {Courtney M P} and Yaw Nyame and Elodi Dielubanza and Chad Achenbach and Kittles, {Rick A}",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0614",
language = "English (US)",
volume = "23",
pages = "2009--2018",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Are HIV-infected men vulnerable to prostate cancer treatment disparities?

AU - Murphy, Adam B.

AU - Bhatia, Ramona

AU - Martin, Iman K.

AU - Klein, David A.

AU - Hollowell, Courtney M P

AU - Nyame, Yaw

AU - Dielubanza, Elodi

AU - Achenbach, Chad

AU - Kittles, Rick A

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: HIV-infected (HIV+) men face cancer treatment disparities that impact outcome. Prostate cancer treatment and treatment appropriateness in HIV+men are unknown. Methods: We used electronic chart review to conduct a retrospective cohort study of 43 HIV+cases with prostate cancer and 86 age- and race-matched HIV-uninfected (HIV-) controls with prostate cancer, ages 40 to 79 years, from 2001 to 2012. We defined treatment appropriateness using National Comprehensive Cancer Network guidelines and the Charlson comorbidity index (CCI) to estimate life expectancy. Results: Median age was 59.5 years at prostate cancer diagnosis. Median CD4+T-cell count was 459.5 cells/ mm3, 95.3% received antiretroviral therapy, and 87.1% were virally suppressed. Radical prostatectomy was the primary treatment for 39.5% of HIV+and 71.0% of HIV- men (P = 0.004). Only 16.3% of HIV+versus 57.0% of HIV- men received open radical prostatectomy (P < 0.001). HIV+men received more radiotherapy (25.6% vs. 16.3%, P = 0.13). HIV was negatively associated with open radical prostatectomy (OR = 0.03, P = 0.007), adjusting for insurance and CCI. No men were undertreated. Fewer HIV+men received appropriate treatment (89.2% vs. 100%, P = 0.003), due to four overtreated HIV+men. Excluding AIDS from the CCI still resulted in fewer HIV+men receiving appropriate treatment (94.6% vs. 100%, P = 0.03). Conclusion: Prostate cancer in HIV+men is largely appropriately treated. Under- or overtreatment may occur from difficulties in life expectancy estimation. HIV+men may receive more radiotherapy and fewer radical prostatectomies, specifically open radical prostatectomies. Impact: Research on HIV/AIDS survival indices and etiologies and outcomes of this prostate cancer treatment disparity in HIV+men are needed.

AB - Background: HIV-infected (HIV+) men face cancer treatment disparities that impact outcome. Prostate cancer treatment and treatment appropriateness in HIV+men are unknown. Methods: We used electronic chart review to conduct a retrospective cohort study of 43 HIV+cases with prostate cancer and 86 age- and race-matched HIV-uninfected (HIV-) controls with prostate cancer, ages 40 to 79 years, from 2001 to 2012. We defined treatment appropriateness using National Comprehensive Cancer Network guidelines and the Charlson comorbidity index (CCI) to estimate life expectancy. Results: Median age was 59.5 years at prostate cancer diagnosis. Median CD4+T-cell count was 459.5 cells/ mm3, 95.3% received antiretroviral therapy, and 87.1% were virally suppressed. Radical prostatectomy was the primary treatment for 39.5% of HIV+and 71.0% of HIV- men (P = 0.004). Only 16.3% of HIV+versus 57.0% of HIV- men received open radical prostatectomy (P < 0.001). HIV+men received more radiotherapy (25.6% vs. 16.3%, P = 0.13). HIV was negatively associated with open radical prostatectomy (OR = 0.03, P = 0.007), adjusting for insurance and CCI. No men were undertreated. Fewer HIV+men received appropriate treatment (89.2% vs. 100%, P = 0.003), due to four overtreated HIV+men. Excluding AIDS from the CCI still resulted in fewer HIV+men receiving appropriate treatment (94.6% vs. 100%, P = 0.03). Conclusion: Prostate cancer in HIV+men is largely appropriately treated. Under- or overtreatment may occur from difficulties in life expectancy estimation. HIV+men may receive more radiotherapy and fewer radical prostatectomies, specifically open radical prostatectomies. Impact: Research on HIV/AIDS survival indices and etiologies and outcomes of this prostate cancer treatment disparity in HIV+men are needed.

UR - http://www.scopus.com/inward/record.url?scp=84907554657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907554657&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0614

DO - 10.1158/1055-9965.EPI-14-0614

M3 - Article

C2 - 25063519

AN - SCOPUS:84907554657

VL - 23

SP - 2009

EP - 2018

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -